

# PHARMACY POLICY STATEMENT

## Marketplace

<b>DRUG NAME</b>	<b>Tarpeyo (budesonide)</b>
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Tarpeyo is a novel formulation of the corticosteroid budesonide that was granted accelerated approval by the FDA in 2021 and converted to a traditional approval in 2023. It is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.

IgA nephropathy is the most common primary glomerular disease. It is an autoimmune condition caused by deposits of immunoglobulin A (IgA) in the kidney, leading to hematuria, proteinuria, and nephropathy (kidney disease) as the kidneys become unable to filter. This can slowly progress to end stage renal disease (ESRD) requiring dialysis or kidney transplant. ACE inhibitors or angiotensin receptor blockers (ARBs) are used to slow the progression of kidney disease, and immunosuppressive agents (i.e., steroids) may be added for those with rapidly progressing disease.

Tarpeyo was the first drug approved specifically for IgAN. As a delayed, sustained release formulation, Tarpeyo is released in a pulse-like manner only once it has reached the small intestine, allowing it to be delivered to the livered tt he r ed r T ed t F dr ped

CareSource considers Tarpeyo (budesonide) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
01/27/2022	New policy for Tarpeyo created.
01/12/2024	Updated references. Removed reauthorization note. Changed UPCR cutoff to match trial criteria instead of that stated in the original labeled indication. Removed “rapid” from risk of disease progression. Specified “primary” IgAN.

References:

1. Tarpeyo [prescribing information]